Intensive BP Control Fails to Cut Heart Risk in Diabetes
A Brazilian trial found no significant drop in major cardiovascular events, though a pooled analysis of three studies showed a 16% reduction.
Updated on Nov. 18, 2026 in Diabetes

Live Poll
Would you take more blood pressure medication to lower your risk if you had diabetes?
In the OPTIMAL-DIABETES trial, patients with type 2 diabetes and high blood pressure who received intensive treatment to a systolic target below 120 mm Hg did not have significantly fewer major cardiovascular events than those on standard care targeting below 140 mm Hg. The trial, conducted at 33 sites in Brazil, enrolled 9,476 patients and found a primary outcome rate of 6% in the intensive group versus 6.7% in the standard group.
Why it matters
The optimal blood pressure target for people with type 2 diabetes remains uncertain, as earlier trials such as ACCORD BP and BPROAD produced inconsistent results. A prespecified meta-analysis combining the three studies showed a 16% relative reduction in major cardiovascular events with intensive lowering, which may inform future treatment guidance.
The OPTIMAL-DIABETES trial recorded a primary outcome hazard ratio of 0.9 (95% CI, 0.77-1.06) with a mean systolic pressure gap of 13.7 mm Hg between arms over a median 4-year follow-up. The renal composite outcome was more frequent with intensive therapy (5.7% vs. 3.7%), and why this occurred is not addressed in the findings.
The players
OPTIMAL-DIABETES
A multicenter, open-label, randomized trial conducted at 33 sites in Brazil that tested intensive versus standard blood pressure targets in type 2 diabetes.
American Heart Association
A leading U.S. nonprofit focused on cardiovascular health whose Scientific Sessions hosted the presentation of the trial results.
The details
Participants with high blood pressure, type 2 diabetes and high cardiovascular risk were randomly assigned to intensive therapy aiming for a systolic reading below 120 mm Hg or standard therapy aiming below 140 mm Hg. The intensive arm took a mean of 3.2 antihypertensive medications, and the trial population had a mean age of 65 with 62% women.
Timeline
2010: ACCORD BP published in NEJM, finding no cardiovascular outcome improvement.
2024: BPROAD published in NEJM, finding cardiovascular outcome improvement.
November 18, 2026: OPTIMAL-DIABETES results presented at the AHA Scientific Sessions in Chicago.
Health Landscape
The results revisit the 2010 ACCORD BP trial, which found no cardiovascular benefit from intensive blood pressure lowering in diabetes, and the later BPROAD trial that reported a benefit. Together the three studies leave the optimal systolic target for patients with type 2 diabetes unsettled, and the pooled analysis favors intensive control despite the single trial's null result.
People with type 2 diabetes and high blood pressure should not change their medication targets based on this single trial alone, since the primary outcome was not significantly improved. Discussing individual blood pressure goals with a clinician remains the practical next step, especially given the trial's reported rise in renal complications with intensive therapy.
The takeaway
Blood pressure targets in diabetes are still being debated, so the benefit of intensive control depends on the outcome measured and the patient's kidney health. Patients should weigh these trade-offs with their healthcare providers rather than treat any single trial as settled guidance.
Further reading
For more on how diabetes affects heart health and treatment options, explore our Diabetes coverage.
Source note: This article includes information reported by Healio.
Live Poll
Would you take more blood pressure medication to lower your risk if you had diabetes?



